Loading…
Ensuring Access to Clinical Trials Act of 2015
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
94pct
272d open
vs 3,548 other S bills in the 114th — cohort avg 43d
This measure has not been amended since it was introduced. The expanded summary of the Senate-passed version is repeated here.) Ensuring Access to Clinical Trials Act of 2015 (Sec. 2) This bill amends the Improving Access to Clinical Trials Act of 2009 to repeal the sunset of, and so extend indefinitely, the exclusion from resources under titles XVI (Supplemental Security Income) and XIX (Medicaid) of the Social Security Act, for eligibility purposes, of compensation in the amount of the first $2,000 per year received by individuals who participate in clinical trials for rare diseases or conditions.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (10)
Became Public Law No: 114-63.
Became Public Law No: 114-63.
Signed by President.
Signed by President.
Presented to President.
Presented to President.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H6276)
Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote.(text: CR H6276)
DEBATE - The House proceeded with forty minutes of debate on S. 139.
Considered under suspension of the rules. (consideration: CR H6276-6279)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
2016 · second_quarter · Health Issues
S.2511 Improving Health Information Technology Act H.R. 6 21st Century Cures Act H.R 5447/S. 3060 Small Business Health Care Relief Act of 2016 S. 2744 Genetic Research Privacy Protection Act H.R. 5273 Helping Hospitals Improve Patient Care Act S. 2713 Advancing Precision Medicine Act S. 1878 The Advancing Hope Act S. 1767 Combination Products Innovation Act S. 1077 Advancing Breakthrough Medical Devices for Patients Act S. 2512 Adding Zika Virus to the FDA Priority Review voucher Program Act S. 1101 Medical Electronic Data Technology Enhancement for Consumers Health Act S. 1597 Patient Focused Impact Assessment Act S. 2055 Medical Countermeasures Innovation Act S. 2873 Expanding Capacity for Health Outcomes (ECHO) Act H.R. 3081/ S. 1778 TELEmedicine for MEDicare (TELE-MED) Act H.R. 4442/S. 2484 CONNECT for Health Act H.R. 1192 National Diabetes Clinical Care Commission Act S. 620, H.R. 1189 Preserving Employee Wellness Programs Act H.R. 4878 Better Care, Lower Cost Act H.R. 5273 Helping Hospitals Improve Patient Care Act H.R. 4774 Training Tomorrows Doctors Today Act S. 2671, H.R.4732 Advancing Medical Resident Training in Community Hospitals Act S. 314, H.R. 592 Pharmacy and Medically and Underserved Areas Enhancement Act H.R.1314 Bipartisan Budget Act H.R. 1190/S. 141 Protecting Seniors' Access to Medicare Act H.R. 160/S. 149 Protect Medical Innovation Act H.R. 4732/ S. 2671 Advancing Medical Resident Training in Community Hospitals Act H.R. 2061, Equitable Access to Care and Health (EACH) Act H.R. 2446 To amend title XIX of the Social Security Act to require the use of electronic visit verification for personal care services furnished under the Medicaid program, and for other purposes. H.R. 2603/S. 1475 Saving Lives, Saving Costs Act H.R. 2646 Helping Families in Mental Health Crisis Act H.R. 2704/H.R. 4212/S.704 Community Based Independence for Seniors Act H.R. 2878/S. 1461 To provide for the extension of the enforcement instruction on supervision requirements for outpatient therapeutic services in critical access and small rural hospitals through 2015. H.R.2911/S. 1697 Small Business Healthcare Relief Act H.R. 3539 Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act H.R. 3660 Preventive Health Savings Act H.R. 3716 Ensuring Terminated Providers are Removed from Medicaid and CHIP Act H.R. 3762 Restoring Americans Healthcare Freedom Reconciliation Act H.R. 3821 Medicaid Directory of Caregivers Act H.R. 5380 Telehealth Parity Act S. 139 Ensuring Access to Clinical Trials Act S. 2023 Prescription Drug Affordability Act S. 2030 Advancing Targeted Therapies for Rare Diseases Act S. 2045 Middle Class Health Benefits Tax Repeal Act S. 2075 American Worker Health Care Tax Relief Act S. 2153 Provider Payment Sunshine Act S. 2187 FDA Regulatory Efficiency Act S. 754 Cyber security Information Sharing Act (CISA) S.2104 Preserving Medicare Advantage for all Medicare Beneficiaries Act
Client expense: $160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2016 · first_quarter · Health Issues
.R. 1020 STEM Education Act H.R. 1190/S. 141 Protecting Seniors' Access to Medicare Act H.R. 1314 Bipartisan Budget Act H.R. 160/S. 149 Protect Medical Innovation Act H.R. 1624/S. 1099, Protecting Affordable Coverage for Employees Act (PACE Act) H.R. 2061, Equitable Access to Care and Health (EACH) Act H.R. 2446 To amend title XIX of the Social Security Act to require the use of electronic visit verification for personal care services furnished under the Medicaid program, and for other purposes. H.R. 2603/S. 1475 Saving Lives, Saving Costs Act H.R. 2646 Helping Families in Mental Health Crisis Act H.R. 4212/S.704 Community Based Independence for Seniors Act H.R. 2745/S. 2102 Standard Mergers & Acquisitions Review Through Equal Rules (SMARTER) Act H.R. 2878/S. 1461 To provide for the extension of the enforcement instruction on supervision requirements for outpatient therapeutic services in critical access and small rural hospitals through 2015. H.R. 2911/S. 1697 Small Business Healthcare Relief Act H.R. 292/S. 2260 Long-Term Studies of Comprehensive Outcomes and Returns for the Economy Act (Long-Term SCORE Act) H.R. 3081/S. 1778 TELEmedicine for MEDicare (TELE-MED) Act H.R. 3539 Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act H.R. 3660 Preventive Health Savings Act H.R. 3716 Ensuring Terminated Providers are Removed from Medicaid and CHIP Act H.R. 3762 Restoring Americans Healthcare Freedom Reconciliation Act H.R. 4469/S.2499 Health Savings Act of 2016 H.R. 4723 Protecting Taxpayers by Recovering Improper Obamacare Subsidy Overpayments Act H.R. 4725 Common Sense Savings Act H.R. 4732/S.2671 Advancing Medical Resident Training in Community Hospitals Act H.R. 4771 Help Efficient, Accessible, Low-cost, Timely Healthcare Act H.R. 4774 Training Tomorrows Doctors Today Act H.R. 4801 Medical Loss Ratio Accountability Act of 2016 H.R. 4832 Health Savings Protection Act H.R. 4848 Healthy Inpatient Procedures (HIP) Act H.R. 4878 Better Care, Lower Cost Act H.R. 5380 Telehealth Parity Act H.R. 6 21st Century Cures Act H.R.4442/S.2484 CONNECT for Health Act S. 1077 Advancing Breakthrough Medical Devices for Patients Act S. 1101 Medical Electronic Data Technology Enhancement for Consumers Health (MEDTECH) Act S. 139 Ensuring Access to Clinical Trials Act S. 1622 FDA Device Accountability Act S. 1945 Mental Health Reform Act of 2016 S. 2023 Prescription Drug Affordability Act S. 2030 Advancing Targeted Therapies for Rare Diseases Act S. 2045 Middle Class Health Benefits Tax Repeal Act S. 2075 American Worker Health Care Tax Relief Act S. 2153 Provider Payment Sunshine Act S. 2187 FDA Regulatory Efficiency Act S. 2343 Telehealth Innovation and Improvement Act S. 2511 Improving Health Information Technology Act S. 2680 Mental Health Reform Act of 2016 S. 2698 Preserving Consumer Health Accounts Act of 2016 S. 2713 Advancing Precision Medicine Act S. 754 Cybersecurity Information Sharing Act (CISA) S. 1101, the Medical Electronic Data Technology Enhancement for Consumers Health (MEDTECH) Act S. 1077, the Advancing Breakthrough Medical Devices for Patients Act. S. 1622, the FDA Device Accountability Act S. 2511, the Improving Health Information Technology Act S. 2680, the Mental Health Reform Act of 2016 S. 2713, the Advancing Precision Medicine Act
Client expense: $160,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · fourth_quarter · Health Issues
H.R. 6 - The 21st Century Cures Act Orphan Drug Tax Credit H.R. 1537/S. 1878 - Advancing Hope Act of 2015 H.R. 209/S. 139 - Ensuring Access to Clinical Trials Act S. 2188 - Rare Disease Innovation Act H.R. 3731 - RAD Fund Act H.R. 3678 - Preserving Access to Orphan Drug Act S. 2030 - Advancing Targeted Therapies for Rare Diseases Act H.R. 2624 - Part D Beneficiaries Appeals Fairness Act S. 1421 - OPEN Act
Client expense: Not reported · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Social Security Administration (SSA)
2015 · fourth_quarter · Health Issues
HR 209/S. 139: Ensuring Access to Clinical Trials Act of 2015; all provisions of the bill HR 2029: Consolidated Appropriations Act, 2016; provisions related to Food and Drug Administration and National Institutes of Health funding HR 605/S. 275: Medicare Home Infusion Site of Care Act of 2015; all provisions of the bill Discussions related to Hawaii Cystic Fibrosis Care Center; provisions related to access
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Medical/Disease Research/Clinical Labs
HR 209/ S. 139: Ensuring Access to Clinical Trials Act of 2015; all provisions of the bill Discussions related to Innovation for Healthier Americans legislation; provisions related to Food and Drug Administration & the National Institutes of Health funding and regulations
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
Health care issues affecting individuals with neuromuscular disease, including transitional health care issues and increased funding for the NIH. H.R. 209/S. 139, Expanding Access to Clinical Trials Act of 2015 (PL 114-63); H.R. 6, 21st Century Cures and Innovation for Healthier Americans initiatives; S. 1604, Transition to Independence Act; H.R. 1516/S. 1013, Ensuring Access to Quality Complex Rehabilitation Technology Act of 2015; S. 1597, Patient-Focused Impact Assessment Act of 2015; S. 2030, Advancing Targeted Therapies for Rare Diseases Act; HR 3229, Enforce the Medicare Improvements for Patients and Providers Act of 2015; S 2425 Patient Access and Medicare Protection Act (PL 114-115)
Client expense: $80,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2015 · fourth_quarter · Health Issues
Health care issues affecting individuals with neuromuscular disease, including transitional health care issues and increased funding for the NIH. H.R. 209/S. 139, Expanding Access to Clinical Trials Act of 2015 (P.L. 114-63); H.R. 6, 21st Century Cures; Innovation for Healthier Americans initiative; H.R. 1516/S. 1013, Ensuring Access to Quality Complex Rehabilitation Technology Act of 2015; S. 1597, Patient-Focused Impact Assessment Act of 2015; and S. 2425, the Patient Access and Medicare Protection Act (P.L. 114-115)
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · fourth_quarter · Health Issues
PL 114 - 20 - the Medicare Access and Chip Reauthorization Act - SGR repeal, CHIP reauthorization, Community Health Center Reauthorization - comments on regulations re: quality measurements, technical support for small businesses, MIPS, APMS HR 293 - the Protect Continuing Physician Education Act and Patient Care Act - regulations implementing the Sunshine Act HR 6 - 21st Century Cures - provisions impacting Sunshine Act S 320 - Medical Innovation Act - NIH funding Opioid Addiction issues S. 1455 - TREAT ACT, Recovery Enhancement for Addiction Act S. 1641 - The Jason Simcakoski Memorial Opioid Safety Act s. 480 - Reauthorization of NASPER - The National All Schedules Prescription Electronic Reporting Act - No specific bill S. 1392 Safer Prescribing of Controlled Substances Act HR 2085/S. 1134 - Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 HR 1462/S 799 - Protecting our Infants Act of 2015 - PL 114-91 Partial Fill legislation - no specific bill Funding for demonstration projects for access to pain specialists - no specific bill DEA - change/classification of regulations regarding partial fill of prescriptions E Prescribing - no specific bill S. 524 - Comprehensive Addiction and Recovery Act of 2015 S. 1134 - Heroin and Prescription Opioid Abuse Education and Enforcement Act Draft CDC Guideline for Prescribing Opioids for Chronic Pain Prescriber Education on the VA System draft legislation Prescription Drug Pricing - no specific bill Direct to Consumer Advertising - no specific bill Negotiating Prescription Drug Prices for Medicare and Medicaid - no specific bill Access to medically tailored food for low income people - no specific bill S 139/HR 209 - the Ensuring Access to Clinical Trials Act of 2015 - PL 114-63 Meaningful Use and Electronic Medical Records - HR 3309 - Future Flexibility on HIT Reporting and Advancing Interoperability Act Opposition to Meaningful Use Stage III Rules HR 3940 - Meaningful Use Hardship Relief Act - PL 114-115 HR 2568 - Fair Medical Audits Act of 2015 DEA Reclassification of marijuana to allow scientific research and study
2015 · fourth_quarter · Health Issues
H.R. 1190, Protecting Seniors' Access to Medicare Act of 2015 H.R. 1314, the Bipartisan Budget Act of 2015 H.R. 1427/S. 804 Medicare CGM Access Act H.R. 1624/S. 1099, the Protecting Affordable Coverage for Employees Act (PACE Act). H.R. 1686, the Preventing Diabetes in Medicare Act H.R. 1726/S. 1345, the Access to Quality Diabetes Education Act H.R. 2029, Consolidated Appropriations Act, 2016 H.R. 2050/S. 2045, the Middle Class Health Benefits Tax Repeal Act of 2015 H.R. 2061, the Equitable Access to Care and Health (EACH) Act H.R. 209/S. 139, the Ensuring Access to Clinical Trials Act H.R. 2102/S. 1131, the Medicare Diabetes Prevention Act H.R. 2205, the Data Security Act of 2015 H.R. 2404/S.1509, The Treat and Reduce Obesity Act H.R. 2446, To amend title XIX of the Social Security Act to require the use of electronic visit verification for personal care services furnished under the Medicaid program, and for other purposes. H.R. 2646, the Helping Families in Mental Health Crisis Act H.R. 2878/ S. 1461, to provide for the extension of the enforcement instruction on supervision requirements for outpatient therapeutic services in critical access and small rural hospitals through 2015. H.R. 2911/S. 1697, the Small Business Healthcare Relief Act H.R. 292/S. 2260, the Long-Term Studies of Comprehensive Outcomes and Returns for the Economy Act (Long-Term SCORE Act) H.R. 3081/S.1778 - TELEmedicine for MEDicare (TELE-MED) Act H.R. 3539, the Reinvigorating Antibiotic and Diagnostic Innovation (READI) Act H.R. 3660, the Preventive Health Savings Act H.R. 3716, the Ensuring Terminated Providers are Removed from Medicaid and CHIP Act H.R. 3762, the Restoring Americans Healthcare Freedom Reconciliation Act H.R. 3821, the Medicaid Directory of Caregivers Act H.R. 4155/S. 2343, the Telehealth Innovation and Improvement Act H.R. 4227/S.2392, the Medicare Advantage Bill of Rights Act H.R. 592/S. 314, Pharmacy and Medically Underserved Areas Enhancement Act H.R. 6, 21st Century Cures Act S. 139, Ensuring Access to Clinical Trials Act of 2015 S. 1945, Mental Health Reform Act of 2015 S. 2023, the Prescription Drug Affordability Act S. 2030, the Advancing Targeted Therapies for Rare Diseases Act S. 2104, A bill to amend title XVIII of the Social Security Act to provide relief to Medicare Advantage plans with a significant number of dually eligible or low-income subsidy beneficiaries and to prevent the termination of two star plans. S. 2141, TRUST IT Act S. 2153, the Provider Payment Sunshine Act, S. 2187, the FDA Regulatory Efficiency Act S. 2425, the Patient Access and Medicare Protection Act S. 754, the Cybersecurity Information Sharing Act (CISA)
2015 · third_quarter · Health Issues
H.R. 6 - The 21st Century Cures Act Orphan Drug Tax Credit H.R. 1537/S. 1878 - Advancing Hope Act of 2015 H.R. 209/S. 139 - Ensuring Access to Clinical Trials Act S. 2188 - Rare Disease Innovation Act H.R. 3731 - RAD Fund Act H.R. 3678 - Preserving Access to Orphan Drug Act S. 2030 - Advancing Targeted Therapies for Rare Diseases Act H.R. 2624 - Part D Beneficiaries Appeals Fairness Act S. 1421 - OPEN Act
Client expense: Not reported · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Social Security Administration (SSA)
2015 · third_quarter · Health Issues
Health care issues affecting individuals with neuromuscular disease, including transitional health care issues and increased funding for the NIH. H.R. 209/S. 139, Expanding Access to Clinical Trials Act of 2015; H.R. 6, 21st Century Cures and Innovation for Healthier Americans initiatives; S. 1604, Transition to Independence Act; H.R. 1516/S. 1013, Ensuring Access to Quality Complex Rehabilitation Technology Act of 2015; S. 1597, Patient-Focused Impact Assessment Act of 2015; S. 2030, Advancing Targeted Therapies for Rare Diseases Act; and HR 3229, Enforce the Medicare Improvements for Patients and Providers Act of 2015
Client expense: $70,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2015 · third_quarter · Health Issues
Health care issues affecting individuals with neuromuscular disease, including transitional health care issues and increased funding for the NIH. H.R. 209/S. 139, Expanding Access to Clinical Trials Act of 2015; H.R. 6, 21st Century Cures and Innovation for Healthier Americans initiatives; S. 1604, Transition to Independence Act; H.R. 1516/S. 1013, Ensuring Access to Quality Complex Rehabilitation Technology Act of 2015; S. 1597, Patient-Focused Impact Assessment Act of 2015; S. 2030, Advancing Targeted Therapies for Rare Diseases Act; and HR 3229, Enforce the Medicare Improvements for Patients and Providers Act of 2015
Client expense: $50,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2015 · third_quarter · Medical/Disease Research/Clinical Labs
HR 209/ S. 139: Ensuring Access to Clinical Trials Act of 2015; all provisions of the bill Bill Not Yet Introduced: Discussions related to Innovation for Healthier Americans legislation; provisions related to Food and Drug Administration & National Institutes of Health funding, laboratory developed tests, pathways for approval of drugs, clinical trial design, & biomedical research
Client expense: $110,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Social Security Administration (SSA), White House Office
2015 · third_quarter · Health Issues
HR 209/S. 139: Ensuring Access to Clinical Trials Act of 2015; all provisions of the bill S. 139: Ensuring Access to Clinical Trials Act of 2015; all provisions of the bill Bill Not Yet Introduced: Discussions related to Innovation for Healthier Americans legislation; provisions related to Food and Drug Administration & National Institutes of Health funding, laboratory developed tests, pathways for approval of drugs, clinical trial design, & biomedical research Bill Not Yet Introduced: Discussions related to Prescription Drug User Fee Act (PDUFA) VI; provisions related to rare diseases, pathways for drugs, expertise in review of rare treatments Bill Not Yet Introduced: Discussions related to Hawaii Cystic Fibrosis Care Center; provisions related to access
Client expense: $110,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Social Security Administration (SSA), White House Office
2015 · third_quarter · Health Issues
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the Senate "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions); S. 2030 Advancing Targeted Therapies for Rare Disease Act of 2015.
Client expense: $330,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · third_quarter · Health Issues
Health care issues affecting individuals with neuromuscular disease, including transitional health care issues and increased funding for the NIH. H.R. 209/S. 139, Expanding Access to Clinical Trials Act of 2015 H.R. 6, 21st Century Cures and Innovation for Healthier Americans initiatives H.R. 1516/S. 1013, Ensuring Access to Quality Complex Rehabilitation Technology Act of 2015 S. 1597, Patient-Focused Impact Assessment Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
PL 114 - 20 - the Medicare Access and Chip Reauthorization Act - SGR repeal, CHIP reauthorization, Community Health Center Reauthorization - preparation for regulations re: quality measurements, technical support, MIPS, APMS HR 293 - the Protect Continuing Physician Education Act and Patient Care Act - regulations implementing the Sunshine Act HR 6 - 21st Century Cures - provisions impacting Sunshine Act S 320 - Medical Innovation Act - NIH funding Opioid Addiction issues S. 1455 - TREAT ACT, Recovery Enhancement for Addiction Act S. 1641 - The Jason Simcakoski Memorial Opioid Safety Act s. 480 - Reauthorization of NASPER - The National All Schedules Prescription Electronic Reporting Act - No specific bill S. 1392 Safer Prescribing of Controlled Substances Act HR 2085/S. 1134 - Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 HR 1462/S 799 - Protecting our Infants Act of 2015 Partial Fill legislation - no specific bill Funding for demonstration projects for access to pain specialists - no specific bill DEA - change/classification of regulations regarding partial fill of prescriptions E Prescribing - no specific bill S. 524 - Comprehensive Addiction and Recovery Act of 2015 S. 1134 - Heroin and Prescription Opioid Abuse Education and Enforcement Act Draft CDC Guideline for Prescribing Opioids for Chronic Pain Prescription Drug Pricing - no specific bill Access to medically tailored food for low income people - no specific bill HR 2519 - Audiology Patient Choice Act of 2015 S 139/HR 209 - the Ensuring Access to Clinical Trials Act of 2015 ICD 10 issues - no specific bill Meaningful Use and Electronic Medical Records - HR 3309 - Future Flexibility on HIT Reporting and Advancing Interoperability Act Stage 3 Final Rules - CMS 42 CFR - Part 412 - 495 - no specific bill HR 2568 - Fair Medical Audits Act of 2015 DEA Reclassification of marijuana to allow scientific research and study
2015 · third_quarter · Budget/Appropriations
Detergent PACS Act of 2015 (S. 588 and H.R. 1139) Ensuring Access to Clinical Trials Act of 2015 (S.139) H.R. 710 - Continuing Appropriations Act S. 1695 - U.S. Senate FY 2016 Labor, HHS Appropriations Act Continuing Appropriations Act, 2016 (H.R. 719) H.R. 3020 - House of Representatives FY 2016 Labor, HHS Appropriations Act
Client expense: $60,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
Electrodiagnostic Accreditation and reimbursement - creating mandatory standards for electrodiagnostic testing (needle EMG and nerve conduction studies) NIH funding of at least $32 billion for federal medical research Ensuring Access to Clinical Trials Act (S. 139/H.R. 209) - This legislation passed the Senate and needs to be passed by the House before financial incentives for patients to participate in rare disease clinical trials lapse later this year Patients Access to Treatments Act (H.R. 1600) - Some conditions diagnosed through EDX testing are progressive and treatment needs to begin as quickly as possible. Restrictive coinsurance requirements on innovative therapies create significant barriers for patients in need of life-changing therapies.
Client expense: $20,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2015 · third_quarter · Health Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine. H.R. 209/S. 139 Ensuring Access to Clinical Trial Act.
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Health Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine. H.R. 209/S. 139 Ensuring Access to Clinical Trial Act.
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Health Issues
Health care issues affecting individuals with neuromuscular disease, including transitional health care issues and increased funding for the NIH. H.R. 209/S. 139, Expanding Access to Clinical Trials Act of 2015; H.R. 6, 21st Century Cures and Innovation for Healthier Americans initiatives; S. 1604, Transition to Independence Act; and H.R. 1516/S. 1013, Ensuring Access to Quality Complex Rehabilitation Technology Act of 2015
Client expense: $50,000 · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2015 · second_quarter · Health Issues
Health care issues affecting individuals with neuromuscular disease, including transitional health care issues and increased funding for the NIH. H.R. 209/S. 139, Expanding Access to Clinical Trials Act of 2015 H.R. 6, 21st Century Cures and Innovation for Healthier Americans initiatives H.R. 1516/S. 1013, Ensuring Access to Quality Complex Rehabilitation Technology Act of 2015
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Budget/Appropriations
Detergent PACS Act of 2015 (S. 588 and H.R. 1139) Ensuring Access to Clinical Trials Act of 2015 (S.139)
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · second_quarter · Medical/Disease Research/Clinical Labs
HR 209: Ensuring Access to Clinical Trials Act of 2015; provisions related to access S. 139: Ensuring Access to Clinical Trials Act of 2015; provisions related to access Docket No: FDA-2014-N-2187: Identifying Potential Biomarkers of Qualifications and Describing Contexts of Use to Address Areas Important to Drug Development; provided regulatory comments on issue
Client expense: $150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE
2015 · second_quarter · Health Issues
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); H.R. 6 The 21st Century Care Act (all provisions); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
Client expense: $300,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · second_quarter · Medical/Disease Research/Clinical Labs
H.R.6 - The 21st Century Cures Act Orphan Drug Tax Credit H.R.1537 - Advancing Hope Act of 2015 H.R.209/S.139 - Ensuring Access to Clinical Trials Act H.R.1600 - Patients' Access to Treatments Act Trade Promotion Authority H.R.1859 - Childrens Access to Specialty Care Act of 2015
Client expense: Not reported · Firm income: Not reported
Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, Social Security Administration (SSA)
2015 · second_quarter · Health Issues
PL 114 - 20 - the Medicare Access and Chip Reauthorization Act - SGR repeal, CHIP reauthorization, Community Health Center Reauthorization HR 293 - the Protect Continuing Physician Education Act and Patient Care Act - regulations implementing the Sunshine Act HR 6 - 21st Century Cures - provisions impacting Sunshine Act S 320 - Medical Innovation Act - NIH funding Opioid Addiction issues S. 1455 - TREAT ACT, Recovery Enhancement for Addiction Act S. 1641 - The Jason Simcakoski Memorial Opioid Safety Act Reauthorization of NASPER - The National All Schedules Prescription Electronic Reporting Act - No specific bill S. 1392 Safer Prescribing of Controlled Substances Act HR 2085/S. 1134 - Heroin and Prescription Opioid Abuse Prevention, Education, and Enforcement Act of 2015 HR 1462/S 799 - Protecting our Infants Act of 2015 HR 2519 - Audiology Patient Choice Act of 2015 S 139/HR 209 - the Ensuring Access to Clinical Trials Act of 2015 ICD 10 issues, letter to CMS - no specific bill Meaningful Use and Electronic Medical Records - no specific bill HR 2568 - Fair Medical Audits Act of 2015
Client expense: $60,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
2015 · first_quarter · Budget/Appropriations
Detergent PACS Act of 2015 (S. 588 and H.R. 1139) Ensuring Access to Clinical Trials Act of 2015 (S.139)
Client expense: $40,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Health Issues
Health care issues affecting individuals with neuromuscular disease, including transitional health care issues. H.R. 209/S. 139, Expanding Access to Clinical Trials Act of 2015 21st Century Cures and Innovation for Healthier Americans initiatives
Client expense: $50,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Health Issues
Health care issues affecting individuals with neuromuscular disease, including transitional health care issues. H.R. 209/S. 139, Expanding Access to Clinical Trials Act of 2015 21st Century Cures and Innovation for Healthier Americans initiatives
Client expense: Not reported · Firm income: $30,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Health Issues
All provisions of the Ensuring Access to Clinical Trials Act of 2015 (S. 139, H.R. 209) Funding for the Food and Drug Administration (FDA) Funding for the National Institutes of Health (NIH) Funding for the Centers for Disease Control (CDC) Funding for the Health Resources and Services Administration (HRSA) Funding for the Center for Medicare and Medicaid Innovation (CMMI) General discussions regarding Childrens Health Insurance Program (CHIP) Reauthorization General discussions regarding 21st Century Cures Initiative General discussions regarding Innovation for Healthier Americans Initiative
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Health Issues
Ensuring Access to Clinical Trials Act of 2015 (S. 139, H.R. 209) Funding for the Food and Drug Administration (FDA) Funding for the National Institutes of Health (NIH) Funding for the Centers for Disease Control (CDC) Funding for the Health Resources and Services Administration (HRSA) Funding for the Center for Medicare and Medicaid Innovation (CMMI) General discussions regarding Childrens Health Insurance Program (CHIP) Reauthorization 21st Century Cures Initiative Innovation for Healthier Americans Initiative
Client expense: $90,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2015 · first_quarter · Health Issues
Issues related to access to rare and orphan disease therapeutics under the enactment of ACA (no specific bills); Issues related to FDA regulatory pathways for pharmaceuticals (no specific bills); Issues related to the "21st Century Cures Act" Discussion Draft (no specific bills); Issues related to the "Innovation for Healthier Americans" Report (no specific bills); H.R. 209/S.139 Ensuring Access to Clinical Trials Act (all provisions)
Client expense: $380,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2015 · first_quarter · Health Issues
HR 2 - the Medicare Access and Chip Reauthorization Act - SGR repeal, CHIP reauthorization, Community Health Center Reauthorization HR 293 - the Protect Continuing Physician Education Act and Patient Care Act - regulations implementing the Sunshine Act 21st Century Cures draft - provisions impacting Sunshine Act S 320 - Medical Innovation Act - NIH funding Opioid Addiction issues HR 1462/S 799 - Protecting our Infants Act of 2015 S 139/HR 209 - the Ensuring Access to Clinical Trials Act of 2015 ICD 10 issues, letter to CMS, no specific bill Meaningful Use and Electronic Medical Records
Client expense: $90,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Mr. Ryan (WI) moved to suspend the rules and pass the bill.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Congress.gov source codes: H11100, H11100-A
Received in the House.
Message on Senate action sent to the House.
Passed Senate without amendment by Unanimous Consent. (consideration: CR S5175; text as passed Senate: CR S5175)
Passed/agreed to in Senate: Passed Senate without amendment by Unanimous Consent.(consideration: CR S5175; text as passed Senate: CR S5175)
Senate Committee on Finance discharged by Unanimous Consent.
Senate Committee on Finance discharged by Unanimous Consent.
Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S105; text of measure as introduced: CR S105)
Introduced in Senate
| Referred to |
| January 8, 2015 |
| January 8, 2015 |
| Enrolled Bill | -- |
| Democratic |
| MI |
| Edward J. Markey | Democratic | MA |
| Jeanne Shaheen | Democratic | NH |
| Kelly Ayotte | Republican | NH |
| Kirsten E. Gillibrand | Democratic | NY |
| Michael F. Bennet | Democratic | CO |
| Orrin G. Hatch | Republican | UT |
| Pat Roberts | Republican | KS |
| Richard J. Durbin | Democratic | IL |
| Roger F. Wicker | Republican | MS |
| Sherrod Brown | Democratic | OH |
| Susan M. Collins | Republican | ME |
Client expense: $80,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
Client expense: $140,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Drug Enforcement Administration (DEA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE